Contineum Therapeutics (CTNM) Total Liabilities (2023 - 2025)
Historic Total Liabilities for Contineum Therapeutics (CTNM) over the last 3 years, with Q3 2025 value amounting to $10.4 million.
- Contineum Therapeutics' Total Liabilities rose 7872.89% to $10.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.4 million, marking a year-over-year increase of 7872.89%. This contributed to the annual value of $14.8 million for FY2024, which is 15922.48% up from last year.
- Latest data reveals that Contineum Therapeutics reported Total Liabilities of $10.4 million as of Q3 2025, which was up 7872.89% from $11.5 million recorded in Q2 2025.
- In the past 5 years, Contineum Therapeutics' Total Liabilities ranged from a high of $14.8 million in Q4 2024 and a low of $3.9 million during Q2 2024
- In the last 3 years, Contineum Therapeutics' Total Liabilities had a median value of $8.5 million in 2024 and averaged $9.0 million.
- The largest annual percentage gain for Contineum Therapeutics' Total Liabilities in the last 5 years was 19849.43% (2025), contrasted with its biggest fall of 7872.89% (2025).
- Contineum Therapeutics' Total Liabilities (Quarter) stood at $5.7 million in 2023, then soared by 159.22% to $14.8 million in 2024, then decreased by 29.8% to $10.4 million in 2025.
- Its Total Liabilities stands at $10.4 million for Q3 2025, versus $11.5 million for Q2 2025 and $13.5 million for Q1 2025.